Radiation oncology firm Accuray's acquisition of TomoTherapy last year provided mixed results for the company in its fiscal 2012 financial report (end-June 30).
For the full year, the company's revenues climbed 84% to $409.2 million, compared with $222.3 million in fiscal 2011. The company's net loss increased to $78.4 million, compared with a net loss of $27.1 million in the last fiscal year.
In the fourth quarter, revenue increased 33% to $100.5 million, compared with $75.2 million in the same quarter of fiscal 2011. The company's net loss improved to $21.6 million, compared with a net loss of $25.4 million in the same quarter a year ago.
CyberKnife revenues in fiscal 2012 slipped to $37.6 million, due to shipment schedules in the European market and a decline in new orders in the Americas. The decrease was partially offset by gains in the Asia-Pacific and Japan regions.
Accuray warned that revenues for its first quarter of fiscal 2013 would be "substantially below" the first quarter of fiscal 2012, but anticipated revenues will "accelerate" over the rest of the fiscal year.
